Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 6/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | ADH1A | P07327 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | ABL2 | P42684 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | PYGL | P06737 | 2/20 | 0.37 |
| ▸ | PYGM | P11217 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10111958 | 1.00 | TP53 (0.44) | TP53POLBNPC1RAB9ARXFP1 | |
| SCHEMBL10111779 | 0.96 | TP53 (0.41) | TP53POLBNPC1RAB9ARXFP1 | |
| SCHEMBL15047618 | 0.94 | EGFR (0.41) | NPC1RAB9AADH1AKITFLT1 | |
| SCHEMBL15765368 | 0.93 | ADH1A (0.38) | TP53POLBNPC1RAB9AADH1A | |
| SCHEMBL468985 | 0.93 | NPC1 (0.39) | TP53POLBNPC1RAB9ARXFP1 | |
| SCHEMBL13564492 | 0.93 | MEN1 (0.41) | TP53POLBNPC1RAB9AADH1A | |
| SCHEMBL14586783 | 0.92 | NPC1 (0.40) | NPC1RAB9ARXFP1ADH1AKIT | |
| SCHEMBL20885067 | 0.92 | HDAC2 (0.38) | TP53POLBNPC1RAB9AADH1A | |
| SCHEMBL20787444 | 0.91 | ADH1A (0.41) | NPC1RAB9ARXFP1ADH1AKIT | |
| SCHEMBL16946488 | 0.91 | ADH1A (0.41) | NPC1RAB9ARXFP1ADH1AKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9192682-B2 | Folate receptor binding conjugates of antifolates | ENDOCYTE, INC. (IN) | 2015-11-24 | — | — | US | disclosed |
| US-20140213760-A1 | Folate Receptor Binding Conjugates of Antifolates | ENDOCYTE, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140154702-A1 | Methods For Treating Cancer Using Combination Therapies | ENDOCYTE INC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140058063-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | ENDOCYTE, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140058063-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | ENDOCYTE, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8546425-B2 | Folate receptor binding conjugates of antifolates | PURDUE RESEARCH FOUNDATION (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120065149-A1 | Vitamin receptor binding drug delivery conjugates | VLAHOV IONTCHO R (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065149-A1 | Vitamin receptor binding drug delivery conjugates | VLAHOV IONTCHO R (US) | 2012-03-15 | — | — | US | disclosed |
| US-8105568-B2 | Vitamin receptor binding drug delivery conjugates | ENDOCYTE, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8105568-B2 | Vitamin receptor binding drug delivery conjugates | ENDOCYTE, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VLAHOV IONTCHO R | 2010-01-07 | — | — | US | disclosed |
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VLAHOV IONTCHO R | 2010-01-07 | — | — | US | disclosed |
| US-7601332-B2 | Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates | ENDOCYTE, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601332-B2 | Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates | ENDOCYTE, INC. (US) | 2009-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213760-A1 | Folate Receptor Binding Conjugates of Antifolates | FOLR1, FOLR2, DHFR | TP53 2848/4885POLB 2418/4885NPC1 904/4885 |
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VDR, CYP2R1, CYP24A1 | TP53 2314/4885POLB 4259/4885NPC1 1188/4885 |
| US-20120065149-A1 | Vitamin receptor binding drug delivery conjugates | VDR, CYP2R1, CYP24A1 | TP53 2314/4885POLB 4259/4885NPC1 1188/4885 |
| US-20140058063-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VDR, CYP2R1, CYP24A1 | TP53 2314/4885POLB 4259/4885NPC1 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.